NCT06409156

Brief Summary

The investigators propose a single-center, assessor blinded, randomized control trial to compare the efficacy of external oblique fascial plane (EOIFP) block versus Oblique Subcostal Transversus Abdominis Plane (OSTAP) block for patients undergoing open upper abdominal surgery at Cleveland Clinic Main Campus.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
8mo left

Started Jun 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Jun 2024Dec 2026

First Submitted

Initial submission to the registry

May 7, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 10, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

June 26, 2024

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

March 18, 2026

Status Verified

March 1, 2026

Enrollment Period

2.5 years

First QC Date

May 7, 2024

Last Update Submit

March 16, 2026

Conditions

Keywords

Abdominal Block

Outcome Measures

Primary Outcomes (1)

  • feasibility for the learning curve of EOIFP Vs OSTAP

    Evaluate feasibility for the learning curve of the new technique of EOIFP versus the standard technique of OSTAP

    3 days

Study Arms (2)

Oblique Subcostal Transversus Abdominis Plane Block

ACTIVE COMPARATOR

Researchers will perform the Oblique Subcostal Transversus Abdominis Plane Block using sterile technique under ultrasound guidance. Once the target is visualized, a 20-gauge, 4-inch echogenic needle will be advanced in-plane to the fascial plane. 5 ml of 0.9% normal saline will be injected through the needle to open the fascial plane and then a single dose (10 ml) of liposomal bupivacaine mixed with 20 mL of bupivacaine 0.25% will be injected on each side.

Procedure: Oblique Subcostal Transversus Abdominis Plane Block

External Oblique Intercostal Fascial Plane block

EXPERIMENTAL

Researchers will perform the External Oblique Intercostal Fascial Plane block using sterile technique under ultrasound guidance. Once the target is visualized, a 20-gauge, 4-inch echogenic needle will be advanced in-plane to the fascial plane. 5 ml of 0.9% normal saline will be injected through the needle to open the fascial plane and then a single dose (10 ml) of liposomal bupivacaine mixed with 20 mL of bupivacaine 0.25% will be injected on each side.

Procedure: External Oblique Intercostal Fascial Plane block

Interventions

With the EOIF block, local anesthetic targets the terminal part of the thoracoabdominal nerves pass behind the costal cartilage and continue anteriorly in the plane between the internal oblique and transversus abdominis muscle, before piercing the rectus abdominis sheath as anterior cutaneous branches supplying the skin of the midabdomen.

Also known as: EOIFP
External Oblique Intercostal Fascial Plane block

With the OSTAP block, local anesthetic is injected into the fascial plane between the posterior rectus sheath and the transversus abdominis muscle beneath the subcostal margin.

Also known as: OSTAP
Oblique Subcostal Transversus Abdominis Plane Block

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Written informed consent;
  • years old;
  • ASA Physical Status 1-3
  • Scheduled for elective open upper abdominal surgery with supraumbilical incision (gastrectomy, hepatectomy, pancreatectomy, splenectomy, supraumbilical ventral hernia repair).
  • Anticipated hospitalization of three nights;
  • Expected requirement for parenteral opioids for at least 48 hours for postoperative pain

You may not qualify if:

  • Hepatic disease, e.g. twice the normal levels of liver enzymes;
  • Chronic kidney disease according to GFR (may be stage 3 or worse as defined by a GFR \<60
  • Allergic reaction to study medications;
  • Women who are pregnant or breastfeeding;
  • Nephrectomy or lower abdominal surgeries such as hysterectomy, colorectal surgeries
  • Patient refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

RECRUITING

Study Officials

  • Ehab Farag, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fabio Rodriguez, MD

CONTACT

Ehab Farag, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
The participant and Outcomes Assessor will be blinded to the patient's allocation.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Single center randomized control trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 7, 2024

First Posted

May 10, 2024

Study Start

June 26, 2024

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

March 18, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations